Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Their research leverages expertise in metabolism to create innovative therapeutics aimed at improving patients' lives. The company has multiple clinical programs, including VK2735, VK2809, and VK0214, targeting various metabolic and rare diseases, with several compounds in different phases of clinical trials.
Industries
Nr. of Employees
small (1-50)
Viking Therapeutics, Inc.
San Diego, California, United States, North America
Products
VK2735 (dual GLP‑1/GIP agonist) — subcutaneous formulation
A dual GLP‑1 and GIP receptor agonist developed as a subcutaneous therapy for obesity and metabolic disorders; reported to have completed early clinical testing and to be in late-stage development.
VK2735 (dual GLP‑1/GIP agonist) — oral formulation
Oral formulation of a dual GLP‑1 and GIP receptor agonist being evaluated in clinical studies for obesity.
VK2809 (thyroid receptor‑β agonist)
Orally available, selective thyroid hormone receptor‑β agonist developed for lipid disorders and nonalcoholic steatohepatitis (NASH/MASH); reported to have met primary and secondary endpoints in a Phase 2b study and reduced LDL‑C and liver fat in Phase 2a.
VK0214 (thyroid receptor‑β agonist for X‑ALD)
Orally available, liver‑selective thyroid receptor‑β agonist in development for X‑linked adrenoleukodystrophy (X‑ALD); Phase 1b data reported reductions in plasma very long‑chain fatty acids and demonstrated tolerability.
VK0612 (FBPase inhibitor)
Orally available, selective inhibitor of fructose‑1,6‑bisphosphatase (FBPase) developed for type 2 diabetes; completed multiple Phase 1 trials and a Phase 2a proof‑of‑concept study showing significant reductions in fasting plasma glucose and other glycemia measures.
VK5211 (selective androgen receptor modulator)
Orally available, non‑steroidal selective androgen receptor modulator (SARM) in development for muscle wasting and cancer cachexia, intended to provide tissue‑selective anabolic effects with oral dosing.
VK2735 (dual GLP‑1/GIP agonist) — subcutaneous formulation
A dual GLP‑1 and GIP receptor agonist developed as a subcutaneous therapy for obesity and metabolic disorders; reported to have completed early clinical testing and to be in late-stage development.
VK2735 (dual GLP‑1/GIP agonist) — oral formulation
Oral formulation of a dual GLP‑1 and GIP receptor agonist being evaluated in clinical studies for obesity.
VK2809 (thyroid receptor‑β agonist)
Orally available, selective thyroid hormone receptor‑β agonist developed for lipid disorders and nonalcoholic steatohepatitis (NASH/MASH); reported to have met primary and secondary endpoints in a Phase 2b study and reduced LDL‑C and liver fat in Phase 2a.
VK0214 (thyroid receptor‑β agonist for X‑ALD)
Orally available, liver‑selective thyroid receptor‑β agonist in development for X‑linked adrenoleukodystrophy (X‑ALD); Phase 1b data reported reductions in plasma very long‑chain fatty acids and demonstrated tolerability.
VK0612 (FBPase inhibitor)
Orally available, selective inhibitor of fructose‑1,6‑bisphosphatase (FBPase) developed for type 2 diabetes; completed multiple Phase 1 trials and a Phase 2a proof‑of‑concept study showing significant reductions in fasting plasma glucose and other glycemia measures.
VK5211 (selective androgen receptor modulator)
Orally available, non‑steroidal selective androgen receptor modulator (SARM) in development for muscle wasting and cancer cachexia, intended to provide tissue‑selective anabolic effects with oral dosing.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Metabolic and endocrine therapeutics
- Diabetes drug development
- Lipid disorders and NASH/MASH development
Key Technologies
- Small-molecule medicinal chemistry
- Peptide/peptidomimetic agonist development
- Receptor-selective agonist design (TRβ, GLP‑1/GIP, amylin/calcitonin)
- Enzyme inhibitor development (FBPase, DGAT‑1)